Here we are again, with markets going wild. In my view, the Nasdaq has entered a bubble. It’s still early, and it could run ...
The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback